ValuEngine lowered shares of Lantheus (NASDAQ:LNTH) from a buy rating to a hold rating in a research note issued to investors on Friday morning.
Several other equities research analysts have also weighed in on the stock. Zacks Investment Research upgraded shares of Lantheus from a hold rating to a strong-buy rating and set a $18.00 target price on the stock in a report on Thursday, August 3rd. Credit Suisse Group increased their target price on shares of Lantheus from $19.00 to $23.00 and gave the stock a neutral rating in a report on Friday, November 3rd. Jefferies Group reiterated a buy rating and issued a $22.00 target price on shares of Lantheus in a report on Thursday, October 12th. Wells Fargo & Company upgraded shares of Lantheus from a market perform rating to an outperform rating in a report on Thursday, November 2nd. Finally, BidaskClub lowered shares of Lantheus from a strong-buy rating to a buy rating in a report on Thursday, August 17th. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The company presently has an average rating of Buy and an average price target of $24.50.
Shares of Lantheus (LNTH) opened at $20.75 on Friday. The company has a quick ratio of 2.46, a current ratio of 2.96 and a debt-to-equity ratio of -3.41. The firm has a market cap of $819.51, a price-to-earnings ratio of 19.51, a price-to-earnings-growth ratio of 1.73 and a beta of 0.94. Lantheus has a twelve month low of $7.95 and a twelve month high of $24.10.
Lantheus (NASDAQ:LNTH) last posted its earnings results on Thursday, November 2nd. The medical equipment provider reported $0.24 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.20 by $0.04. The company had revenue of $79.94 million for the quarter, compared to analyst estimates of $77.18 million. Lantheus had a net margin of 9.59% and a negative return on equity of 46.45%. The business’s revenue for the quarter was up 9.4% compared to the same quarter last year. During the same period last year, the business posted $0.15 earnings per share. sell-side analysts anticipate that Lantheus will post 1.05 EPS for the current year.
In related news, CFO John W. Crowley sold 6,755 shares of the firm’s stock in a transaction on Friday, October 13th. The shares were sold at an average price of $18.41, for a total transaction of $124,359.55. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Timothy G. Healey sold 11,314 shares of the firm’s stock in a transaction on Friday, November 17th. The stock was sold at an average price of $21.51, for a total transaction of $243,364.14. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 246,777 shares of company stock worth $4,258,192. 2.30% of the stock is currently owned by company insiders.
Large investors have recently modified their holdings of the stock. Thrivent Financial For Lutherans acquired a new stake in shares of Lantheus during the second quarter worth $321,000. Royce & Associates LP acquired a new stake in Lantheus in the 2nd quarter valued at $4,896,000. Schwab Charles Investment Management Inc. acquired a new stake in Lantheus in the 2nd quarter valued at $770,000. QS Investors LLC acquired a new stake in Lantheus in the 2nd quarter valued at $2,256,000. Finally, Prudential Financial Inc. acquired a new stake in Lantheus in the 2nd quarter valued at $835,000. Institutional investors and hedge funds own 91.95% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Lantheus (LNTH) Downgraded by ValuEngine to “Hold”” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2017/12/05/lantheus-lnth-downgraded-by-valuengine-to-hold.html.
Lantheus Holdings, Inc is engaged in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its imaging agents and products are used across a range of imaging modalities, including echocardiography and nuclear imaging.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Lantheus Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.